|Articles|March 1, 2009

MANAGED INNOVATION,ASSURED COMPLIANCE-SAS Whitepaper

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

Recruitment in the Age of AI: Q&A with John Worden, Javara

ByJohn Worden,Andy Studna, Senior Editor

September 10th 2026

What It Actually Means to Embed the Patient Voice in Trial Design

ByAmélie Lothe,Andy Studna, Senior Editor

September 10th 2026

ACT Brief: Explainable AI for Patient Subgroups, Participant Understanding and Engagement, and FDA Leadership Stabilization

ByAndy Studna, Senior Editor

September 10th 2026

© putilov_denis - © putilov_denis - stock.adobe.com

From Participation to Understanding: Reframing Engagement in Clinical Trials

ByAubrey Verna

September 9th 2026

Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable

ByOtis Johnson, PhD, MPA,Joseph Geraci, PhD,Andy Studna, Senior Editor

September 9th 2026

MANAGED INNOVATION,ASSURED COMPLIANCE-SAS Whitepaper

Related Content

Recruitment in the Age of AI: Q&A with John Worden, Javara

What It Actually Means to Embed the Patient Voice in Trial Design

ACT Brief: Explainable AI for Patient Subgroups, Participant Understanding and Engagement, and FDA Leadership Stabilization

From Participation to Understanding: Reframing Engagement in Clinical Trials

Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable

Trending on Applied Clinical Trials Online

What It Actually Means to Embed the Patient Voice in Trial Design

Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable

ACT Brief: Explainable AI for Patient Subgroups, Participant Understanding and Engagement, and FDA Leadership Stabilization

What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale

ACT Brief: RBQM Multi-Functional Buy-In and E6(R3), Site Payment Performance and Cash Runway, and Inhaled Therapy for Cystic Fibrosis